About Ceroid-lipofuscinosis neuronal protein 6
Ceroid-lipofuscinosis neuronal protein 6 (CLN6) is a protein
from Homo sapiens identified by UniProt accession
Q9NWW5, 311 residues long.
MolForge cross-references it against 0 known binders and
83 disease associations.
Target properties
| Protein name | Ceroid-lipofuscinosis neuronal protein 6 |
|---|
| UniProt accession | Q9NWW5 |
|---|
| Gene | CLN6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 311 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (83)
Diseases linked to this target (Open Targets).
- CLN6 disease · score 0.83
- ceroid lipofuscinosis, neuronal, 6A · score 0.81
- ceroid lipofuscinosis, neuronal, 6B (Kufs type) · score 0.81
- CLN4A disease · score 0.80
- neuronal ceroid lipofuscinosis · score 0.67
- adult neuronal ceroid lipofuscinosis · score 0.55
- genetic disorder · score 0.45
- Abnormality of the nervous system · score 0.44
- cystic fibrosis · score 0.34
- Neurodevelopmental disorder · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NWW5-F1 | alphafold | PREDICTED | 84.96 | — |
Amino-acid sequence (311 residues)
MEATRRRQHL GATGGPGAQL GASFLQARHG SVSADEAART APFHLDLWFY FTLQNWVLDF GRPIAMLVFP LEWFPLNKPS VGDYFHMAYN VITPFLLLKL IERSPRTLPR SITYVSIIIF IMGASIHLVG DSVNHRLLFS GYQHHLSVRE NPIIKNLKPE TLIDSFELLY YYDEYLGHCM WYIPFFLILF MYFSGCFTAS KAESLIPGPA LLLVAPSGLY YWYLVTEGQI FILFIFTFFA MLALVLHQKR KRLFLDSNGL FLFSSFALTL LLVALWVAWL WNDPVLRKKY PGVIYVPEPW AFYTLHVSSR H
Explore Ceroid-lipofuscinosis neuronal protein 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets